As states authorize and implement Prescription Drug Affordability Boards, health care stakeholders have raised concerns about both their decision-making processes and the potential negative consequences of those decisions. PDABs are inherently state-based...

Everyone knows you can’t compare apples and oranges. Yet that’s exactly what prescription drug affordability boards do when they make decisions about value.

Specialty doctors are concerned about the harmful impacts of prescription drug affordability boards, a white paper commissioned by the Value of Care Coalition recently found. 

While some states continue to struggle with the operations of Prescription Drug Affordability Boards (PDABs), others are saying “no” to upper payment limits altogether. This year, the governors of Virginia and Nevada vetoed legislation that would have either...

In recent years, prescription drug affordability boards (PDABs) have struggled as they implement their cost review and price-setting policies. Now, some states are attempting to cut out these regulatory processes entirely. Instead of creating new PDABs, some states...

The March meeting of the Maryland Prescription Drug Affordability Board (PDAB)  ignited significant concerns among a broad group of patient, physician, pharmacist and caregiver organizations. Recent legislation requires the PDAB to conduct an analysis on the impact of...

An oft-repeated talking point for proponents of prescription drug affordability boards is that capping the top-line price of medications will result in lower premiums and out-of-pocket spending by patients. But a new report from the Partnership to Fight Chronic...

A new cost-benefit analysis from Colorado’s Department of Regulatory Agencies reveals a concerning finding.

VCC examines the guidance being given to PDABs and why the suggestions are concerning. 

Prescription Drug Affordability Boards (PDABs) claim to save patients money, but state records show a years-long trail of millions spent with no savings produced. The first PDAB was created in 2019 under the guise of lowering health care costs for people in Maryland,...